PreVenTB Trial: Considerations for Interpreting Extrapulmonary Tuberculosis Efficacy and Tuberculin Skin Test-Stratified Analyses

Why It Matters

Accurate interpretation of TST conversion and extrapulmonary efficacy is crucial for shaping TB vaccine development pathways and informing WHO‑aligned regulatory strategies.

Key Takeaways

• VPM1002 induced 23.1% TST conversion vs 20.3% placebo at six months
• Vaccine showed 68.4% TB efficacy; TST conversion may be false‑positive
• Extrapulmonary TB efficacy reached 50.4%, far above 19.5% for pulmonary disease
• Diagnostic variability across sites may inflate extrapulmonary efficacy estimates
• Child subgroup suggests promise, but only 7 vs 20 events limit conclusions

Pulse Analysis

The PreVenTB trial represents one of the most extensive government‑funded evaluations of tuberculosis vaccines, enrolling over 12,700 contacts across 18 Indian sites. While the double‑blind design and a 96.7% follow‑up rate during the COVID‑19 pandemic underscore its methodological rigor, the primary efficacy endpoint—preventing microbiologically confirmed TB—was not achieved for either VPM1002 or Immuvac. This outcome highlights the persistent challenge of translating immunogenicity signals into real‑world protection, a hurdle that continues to shape the global TB vaccine pipeline.

A pivotal nuance in the trial’s findings concerns the tuberculin skin test (TST) conversion rates. VPM1002 participants exhibited a modestly higher conversion (23.1% vs 20.3% placebo) at six months, a difference the authors deemed statistically insignificant for infection prevention. However, because live BCG‑derived vaccines can trigger TST reactivity independent of Mycobacterium tuberculosis exposure, this conversion may overstate true infection rates. Interferon‑gamma release assays, which target RD1 antigens absent from BCG, could have offered a clearer distinction between vaccine‑induced responses and genuine latent infection, refining efficacy calculations.

The trial’s most striking result is the 50.4% efficacy against extrapulmonary TB, contrasted with 19.5% for pulmonary disease. While biologically plausible—central memory CD4+ T cells may curb hematogenous spread—diagnostic variability across the diverse study sites likely influences this gap. Extrapulmonary TB diagnosis often relies on invasive sampling and heterogeneous laboratory capacity, potentially inflating efficacy signals. Moreover, post‑hoc subgroup analyses in children suggest promise but rest on a handful of events, underscoring the need for larger, pre‑specified pediatric trials before policy shifts such as booster schedules can be justified. These insights collectively inform the next generation of TB vaccine studies and align with WHO’s preferred product characteristics for future candidates.